WO2010001926A1 - 含水組成物 - Google Patents
含水組成物 Download PDFInfo
- Publication number
- WO2010001926A1 WO2010001926A1 PCT/JP2009/062036 JP2009062036W WO2010001926A1 WO 2010001926 A1 WO2010001926 A1 WO 2010001926A1 JP 2009062036 W JP2009062036 W JP 2009062036W WO 2010001926 A1 WO2010001926 A1 WO 2010001926A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- soluble
- residue
- containing composition
- absorber
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
Definitions
- the present invention relates to a water-containing composition that can be used as cosmetics, external preparations for skin, and the like.
- the water-containing composition may be a water-containing composition in which a blended water-soluble drug or water-soluble dye is stabilized.
- UV absorbers that are difficult to dissolve in water (poorly water-soluble UV absorbers) are useful in the field of external use for skin, such as cosmetics and skin external preparations, and these UV absorbers can be stably incorporated into external compositions.
- Various techniques for inclusion are provided. As a representative technique, an emulsification technique or a solubilization technique can be given. And in terms of the technique that can distribute the ultraviolet absorbent to the skin with a refreshing feel, a solubilization technique and an underwater dispersion technique can be mentioned.
- the solubilization technique is an indispensable technique when the ultraviolet absorber is used in the form of a lotion or the like.
- a solubilizer of the ultraviolet absorber polyoxyethylene alkyl ether or polyoxyethylene curing Surfactants such as castor oil are used. *
- Patent Document 1 use of ethoxylated phytosterol and phytostanol is reported as a means for dissolving a poorly water-soluble pharmaceutical agent.
- this preparation realizes an aqueous solution of a pharmaceutical agent for the purpose of preventing cell damage in living cells, and there is no mention about the description and use of an ultraviolet absorber.
- ultraviolet absorbers can also be used as water-soluble pigments and water-soluble drug stabilizers.
- Water-soluble pigments are mainly used as colorants in the field of external use in the skin such as cosmetics and external preparations. These water-soluble dyes are known to decompose and fade when contacted with ultraviolet rays from sunlight or the like.
- water-soluble drugs manufactured of which are used as active ingredients of pharmaceuticals
- various techniques for stabilizing and blending water-soluble pigments and drugs have been provided. As an example, there is a co-blending of the above-described stabilization target component and an ultraviolet absorber.
- Patent Document 2 use of a water-soluble ultraviolet absorber is reported as a means for stabilizing cosmetics in which an L-ascorbic acid derivative is dissolved.
- an oil-soluble UV absorber that is highly effective in this preparation, and there is no mention of fading of water-soluble dyes.
- An object of the present invention is to provide a water-containing composition in which a poorly water-soluble ultraviolet absorber is solubilized or dispersed in water. Further, the poorly water-soluble ultraviolet absorber is dissolved in water to form a water-soluble composition.
- the invention aims to realize stabilization of these water-soluble components by coexisting with a chemical agent and a water-soluble dye.
- the present inventors have studied a surfactant capable of dissolving a poorly water-soluble UV absorber in water, and added phytosterol or phytostanol added with polyoxyethylene, In the aqueous system, it was found that the ultraviolet absorbent can be dissolved by coexisting with a poorly water-soluble ultraviolet absorbent, and the present invention was completed.
- the present invention provides a water-containing composition (hereinafter also referred to as the water-containing composition of the present invention) containing the following components (1) to (3).
- a water-containing composition hereinafter also referred to as the water-containing composition of the present invention
- the present inventor conducted studies on the stabilization of drugs and pigments when a poorly water-soluble UV absorber was dissolved in water, and the above compound (I) was absorbed in a water system with a poorly water-soluble UV absorber.
- the present invention has been completed by discovering that it can be dissolved in a coexistent state with an agent, a water-soluble drug and a water-soluble dye, and that the water-soluble component can be sufficiently stabilized.
- the present invention provides a water-containing composition (1) to (3) containing a water-soluble drug and / or a water-soluble dye and containing the components (1) to (3) blended in the water-containing composition of the present invention.
- a stabilized composition of the present invention a water-soluble drug and / or a water-soluble dye are added to the components (1) to (3) and the water-containing composition.
- the invention also provides a method for stabilizing a water-soluble component (hereinafter also referred to as the stabilization method of the present invention).
- Compound (I) has the following formula:
- the group on the right side of the polyoxyethylene chain portion of this chemical formula is a phytosterol residue or a phytostanol residue that R can take.
- the “water-containing composition” means a composition containing water.
- the “dissolved state” referred to in the present specification means that the UV absorber is “transparent or translucent state” in the system when the visual observation is performed without the influence of other components. It means a state that is recognized to exist evenly. Examples of the “transparent or translucent state” include, for example, a “solubilized state” in which a poorly water-soluble UV absorber is thermodynamically stable, or the UV absorber is dispersed as fine particles in an aqueous phase. “Dispersed in water” can be mentioned.
- the water-containing composition of the present invention can typically be used as an external composition applicable to the skin or a base thereof.
- Specific product forms of the composition for external use include cosmetics and skin external preparations. Both cosmetics and external preparations for skin are forms that can be applied to the skin, and they are overlapping concepts. In particular, being a cosmetic means that it is also an external preparation for skin. . When it is a skin external preparation and not a cosmetic, the purpose of the skin external preparation is not “makeup” whose primary purpose is beauty, but its primary purpose is health, that is, “quasi-drug” Or the case of “medicine”.
- a water-containing composition in which a poorly water-soluble UV absorber is solubilized or dispersed in water (the water-containing composition of the present invention)
- a water-soluble drug and / or water-soluble dye is stabilized.
- a water-containing composition (the stabilizing composition of the present invention) formulated in a fresh state and (3) a method for stabilizing a water-soluble drug and / or water-soluble dye in the water-containing composition of the present invention (stabilization of the present invention) Method).
- [A] Water-containing composition of the present invention [A-1] Blending of polyoxyethylene addition compound (compound (I)) In the water-containing composition of the present invention, as described above, together with water and a poorly water-soluble UV absorber Compound (I) is blended. As described later, compound (I) is blended in the water-containing composition of the present invention as only one compound within the range of the above formula (I), and blended as a mixture of two or more different compounds. Is possible.
- phytosterol which is a parent compound of the phytosterol residue that R can take
- phytosterol residues that R can take include sitosterol residues, campesterol residues, stigmasterol residues, brassicasterol residues, avenasterol residues, ergosterol residues, and the like.
- the compound (I) to be blended in the water-containing composition of the present invention can be a mixture of two or more compounds having different phytosterol residues.
- phytostanol which is a parent compound of a phytostanol residue that R can take
- blended in the water-containing composition of this invention can also be a mixture of 2 or more types of compounds which are phytostanol residues from which R differs as mentioned above.
- the compound (I) is a water-containing composition of the present invention as a mixture of a compound having R having one or more phytosterol residues and a compound having one or more phytostanol residues. It is also possible to blend in.
- n indicating the number of polyoxyethylene chains in the compound (I) is 5 to 100, preferably 5 to 50.
- Compound (I) can be produced using a conventional method based on its chemical structure.
- phytosterol can be added with ethylene oxide in the presence of a catalyst to carry out an addition reaction, and after removal of unreacted substances, neutralization, dehydration, deodorization and filtration can be performed to easily produce compound (I). it can.
- the amount of compound (I) in the water-containing composition of the present invention is 10% by mass or less, preferably 3% by mass or less, based on the composition. Further, the compounding amount of the compound (I) largely depends on the relative relationship with the compounding amount of the poorly water-soluble UV absorber.
- the upper limit of the abundance ratio of the compound (I) to the poorly water-soluble UV absorber is preferably 1 or more in terms of mass ratio, with the upper limit of the compounding amount of the compound (I) as a limit index. Is particularly preferred.
- the suitable value of the minimum of the compounding quantity of compound (I) can also be prescribed
- compound (I) is an essential compounding component of the water-containing composition of the present invention, and this compounding amount does not become 0% by mass.
- [A-2] Formulation of poorly water-soluble UV absorber In the water-containing composition of the present invention, one or more poorly water-soluble UV absorbers are mixed and solubilized or dispersed in water. It is necessary.
- the solubility in a solvent other than water in the poorly water-soluble UV absorber is not particularly limited.
- the blending of this poorly water-soluble UV absorber does not interfere with the selective blending of the water-soluble UV absorber.
- UV absorbers typically bisresorcinyl triazine, more specifically bisethylhexyloxyphenol methoxyphenyl triazine (also known as 2,4-bis ⁇ [4- (2-Ethylhexyloxy) -2-hydroxy] phenyl ⁇ -6- (4-methoxyphenyl) 1,3,5-triazine, commercially available TINOSORB S, Ciba Specialty Chemicals) Octyltriazone (alias: 2,4,6-tris ⁇ 4- (2-ethylhexyloxycarbonyl) anilino ⁇ 1,3,5-triazine, or 2,4,6-trianilino-p- (carbo-2 '-Ethylhexyl-1'-oxy) -1,3,5-triazine, commercially available ubinal T150 (UVINUL T150) BASF), 2- [2-hydroxy-4- (2-ethyl)
- UV absorbers under such conditions include bisethylhexyloxyphenol methoxyphenyl triazine, 2,4,6- And triazine derivatives such as tris [4- (2-ethylhexyloxycarbonyl) anilino] 1,3,5-triazine, 2- [2-hydroxy-4- (2-ethylhexyl) phenoxy] -2H-benzotriazole.
- bisethylhexyloxyphenol methoxyphenyltriazine is preferred.
- UV absorbers having absorption in the UVA region tend to have excellent stabilizing effects on water-soluble pigments and water-soluble drugs, and are poorly water-soluble to be selected when producing the stabilizing composition of the present invention described later. It is advantageous as an ultraviolet absorber.
- UV absorbers examples include bisethylhexyloxyphenol methoxyphenyltriazine, 2,4,6-tris [4- (2-ethylhexyloxycarbonyl) anilino] 1,3,5-triazine, 2 -[2-hydroxy-4- (2-ethylhexyl) phenoxy] -2H-benzotriazole, 4-tert-butyl-4'-methoxydibenzoylmethane, 2- [4- (diethylamino) -2-hydroxybenzoyl] benzoic acid An acid hexyl ester etc. can be mentioned.
- the blending amount of the poorly water-soluble ultraviolet absorber in the water-containing composition of the present invention is as long as the poorly water-soluble ultraviolet absorber in the composition can maintain the state of being solubilized or dispersed in water at room temperature.
- the relationship between the amount of the poorly water-soluble UV absorber and the amount of compound (I) is as described above. It is also possible to determine the specific blending amount in consideration of the properties of each ultraviolet absorber within the limits of the blending amount relationship.
- the water in the water-containing composition of the present invention is usually ion-exchanged water, purified water, or tap water.
- the total amount of compound (I) and poorly water-soluble UV absorber in the entire composition, or compound (I), poorly water-soluble UV absorber and general ingredients in the entire composition The remaining amount can be included.
- the water-containing composition of the present invention In the water-containing composition of the present invention, due to the presence of the compound (I), an inherently poorly water-soluble UV absorber is easily solubilized or water Decentralized.
- the water-containing composition of the present invention is prepared by, for example, preparing a part in which a poorly water-soluble UV absorber is dissolved or dispersed in Compound (I), and mixing or solubilizing or dispersing it in the aqueous phase. A composition can be produced.
- the water-containing composition of the present invention containing only the above essential components can be used as an external composition used as a cosmetic or a skin external preparation.
- properties such as a medicinal effect and an ultraviolet ray shielding action of the poorly soluble ultraviolet absorbent solubilized or dispersed in water can be utilized for the outer skin.
- the water-containing composition of the present invention containing only these essential components can be used as a base for an external composition in which other general components are blended. That is, firstly, the water-containing composition of the present invention having the basic formulation containing only the essential components described above is manufactured, and secondly, optional components are blended as necessary to achieve the final purpose.
- the external composition of the aspect to perform (The said external composition is also the water-containing composition of this invention) can be manufactured.
- Common ingredients here include excipients, buffers, salts, antioxidants, for the addition of medicinal properties, coloring, adjustment of manufacturing parameters, adjustment of ionic strength, adjustment of pH, stability of the formulation, etc.
- Preservatives, fragrances, surfactants, water-soluble vitamins and the like can be mentioned.
- a water-soluble substance is usually used, but an oil-soluble component is acceptable depending on the dosage form of the final product.
- a liquid oil that does not have a six-membered ring due to its structure can be used as the general component.
- the production method is not limited to the exemplified production method, and the production method of the water-containing composition of the final form of the present invention is appropriately selected or devised according to the nature of the necessary and selected general components. be able to.
- the stabilized composition of the present invention contains the water-soluble drug and the water-containing composition of the present invention described above. Both or any one of the water-soluble dyes is a water-containing composition in which one kind or two or more kinds are blended. Therefore, the above-described book is used for the blending of (1) compound (I), (2) poorly water-soluble UV absorber, and (3) water, which are blended as essential components of the stabilizing composition of the present invention. According to the description of (A-1), (A-2) and (A-3) of the stabilized composition of the invention.
- the water-soluble dye to be stabilized in the stabilizing composition of the present invention is not particularly limited, but for example, red 3 No. (erythrosin), Red No. 102 (New Coxin), Red No. 106 (Acid Red), Red No. 201 (Risor Rubin B), Red No. 227 (Fastashid Magenta), Red No. 230 (1) (Erythrosin YS) ), Red 203 (2) (erythrosine YSK), red 231 (phloxine BK), red 232 (rose bengal K), red 401 (violamine R), red 502 (Bonso 3R), red 503 (Bonso R), Red No.
- the water-soluble drug to be stabilized by the stabilization composition of the present invention is not particularly limited.
- L-ascorbic acid vitamin C
- vitamin C derivatives include ascorbic acid inorganic salt esters such as L-ascorbic acid monophosphate, L-ascorbic acid-2-sulfate, and dl- ⁇ -tocopherol 2-L-ascorbic acid diester; And ascorbic acid-2-glycoside such as 2-O- ⁇ -D-glucopyranosyl-L-ascorbic acid.
- salts include alkali metal salts (Na salts, K salts, etc.), alkaline earth metal salts (Ca salts, Mg salts, etc.), ammonium Examples include salts, alkanolamine salts, amino acid salts, and the like, and alkali metal salts are preferable.
- salicylic acid and a salicylic acid derivative are mentioned as the stabilization object in the stabilization composition of this invention.
- the alkoxysalicylic acid-based whitening agent that is a salicylic acid-based derivative include, for example, those described in JP-A-6-40886. Specific examples include 3-methoxysalicylic acid, 3-ethoxysalicylic acid, 4-methoxysalicylic acid, 4-ethoxysalicylic acid, 4-propoxysalicylic acid, 4-isopropoxysalicylic acid, 4-butoxysalicylic acid, 5-methoxysalicylic acid, 5-ethoxysalicylic acid. , 5-propoxyxalicylic acid, or a salt thereof.
- the salt examples include alkali metal salts (Na salt, K salt, etc.), alkaline earth metal salts (Ca salt, Mg salt, etc.), ammonium salts, alkanolamine salts, amino acid salts, etc., preferably alkali metal salts. .
- tranexamic acid and further, tranexamic acid derivatives can be blended in the stabilized composition of the present invention as a water-soluble drug.
- the tranexamic acid derivative include a dimer of tranexamic acid [eg, trans-4- (transaminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid], an ester of tranexamic acid and hydroquinone (eg, trans- 4-aminomethylcyclohexanecarboxylic acid 4′-hydroxyphenyl ester), an ester of tranexamic acid and gentisic acid [eg, 2- (trans-4-aminomethylcyclohexanecarbonyloxy) -5-hydroxybenzoic acid and Salts thereof], amides of tranexamic acid [eg, trans-4-aminomethylcyclohexanecarboxylic acid methylamide and salts thereof, trans-4- (p-methoxybenzoyl) aminomethyl
- amino acids such as glycine, alanine, valine, leucine, threonine, phenylalanine, tyrosine, aspartic acid, asparagine, glutamine, taurine, arginine, histidine, and alkali metal salts and hydrochlorides thereof; acyl sarcosine acid (for example, lauroyl sarcosine sodium) Glutathione; organic acids such as citric acid, malic acid, tartaric acid and lactic acid; vitamin A and its derivatives; vitamin B 6 hydrochloride, vitamin B 6 tripalmitate, vitamin B 6 dioctanoate, vitamin B 2 and its derivatives, vitamin B 12, vitamin B such as vitamin B 15 and its derivatives; vitamin E; vitamin D; vitamin H, pantothenic acid, vitamins such as pantethine; nicotinamide, benzyl nicotinate, .gamma.-oryzanol, allantoin, grayed Stilin
- the water-soluble drug that can be blended in the stabilizing composition of the present invention is not particularly limited as long as it is usually used in cosmetics.
- vitamin C vitamin C derivatives, salicylic acid, salicylic acid derivatives, tranexamic acid, or the above are particularly suitable for blending in the stabilized composition of the present invention.
- tranexamic acid a water-soluble drug listed here.
- medical agent used as a salt as a stabilization object component in the stabilization composition of this invention
- the alkali agent for neutralizing the water-soluble drug as such a salt is not particularly limited as long as it can form a salt.
- metal hydroxides such as sodium hydroxide and potassium hydroxide; alkanolamines such as monoethanolamine, diethanolamine and triethanolamine; organic acid salts such as sodium citrate, potassium malate and sodium lactate, and amino acids such as lysine Etc.
- alkali metal hydroxides such as sodium hydroxide and potassium hydroxide are preferred.
- the inherently poorly water-soluble UV absorber is easily solubilized by the presence of the compound (I). Alternatively, it is dispersed in water.
- a part in which a poorly water-soluble UV absorber is dissolved or dispersed in Compound (I) is prepared, and this is mixed with an aqueous phase containing a water-soluble drug or a water-soluble dye to be stabilized.
- the stabilized composition of the present invention can be produced by solubilization or dispersion.
- the stabilizing composition of the present invention containing only the above essential components can be used as an external composition used as a cosmetic or an external preparation.
- the properties of the solubilized or water-dispersed poorly soluble ultraviolet absorber such as the medicinal properties and the ultraviolet shielding effect, are applied to the outer skin (scalp. (Including hair).
- the stabilized composition of the present invention containing only these essential components can be used as a base for an external composition containing other general components. That is, firstly, the stabilized composition of the present invention having a basic formulation containing only the above essential components is manufactured, and secondly, optional components are blended as necessary, and the final purpose
- the composition for external use of the aspect (The said composition for external use is also the stabilization composition of this invention) can be manufactured.
- Common ingredients here include excipients, buffers, salts, antioxidants, preservatives, perfumes, interfaces for adjustment of manufacturing parameters, adjustment of ionic strength, pH adjustment, formulation stability, etc.
- An active agent, a water-soluble vitamin, etc. can be mentioned.
- a general component a water-soluble substance is usually used, but an oil-soluble component is acceptable depending on the dosage form of the final product.
- a liquid oil that does not have a six-membered ring due to its structure can be used as the general component.
- the stabilized composition of the present invention in the final target form without going through the production of the stabilized composition of the present invention having the above basic formulation.
- an aqueous phase prepared by dissolving a water-soluble component selected as a general component in addition to the above-described water-soluble dye and water-soluble drug in water is prepared.
- a soluble ultraviolet absorber is dissolved or dispersed in the compound (I)
- the ultraviolet absorber is solubilized or water-dispersed, and the final form of the stabilized composition of the present invention is obtained.
- the production method is not limited to the exemplified production method, and the production method of the stabilization composition of the present invention in the final form is appropriately selected or devised according to the nature of the necessary and selected general components. can do.
- the stabilization method of the present invention substantially stabilizes a water-soluble dye and / or a water-soluble drug in the stabilization composition of the present invention.
- Implementation of the method and the stabilization composition of the present invention is necessarily consistent with the implementation of the stabilization method of the present invention.
- the blending amount is mass% relative to the blending target.
- the description of this example is broadly classified into disclosure relating to the water-containing composition of the present invention (Group A) and description relating to the stabilizing composition (Group B).
- Example concerning water-containing composition [Test Example A]
- compound (I) or other surfactant and UV absorber are mixed and dissolved, and the parts are mixed in water to obtain test products shown in Tables A1 to A6 (Examples) Or a comparative example) was obtained and a test according to the following criteria was performed. The results are listed separately for each table.
- “-” in the column indicating the blending amount in each table indicates 0 mass%.
- “POE” is an abbreviation for “polyoxyethylene”
- POP is an abbreviation for “polyoxypropylene”.
- test over time (a) Confirmation of change in dissolution state
- the test product prepared as described above was stored at 50 ° C. for 1 month (hereinafter also referred to as “50 ° C. 1M”), and again in the above procedure.
- the L value was measured.
- the stability over time was evaluated based on the difference between the L value measured immediately after the preparation of the test product and the L value measured this time. Judgment criteria are as follows. The L value measured this time is also listed in each table.
- Comparative Examples A1 and A2 use a surfactant having no phytosteryl skeleton, so that the solubilizing ability is low and it is not suitable for the solubilization of the ultraviolet absorber.
- Examples A1 to A3 use the compound (I) having a phytosteryl skeleton as a surfactant, and solubilize a triazine-based UV absorber that is a water-insoluble UV absorber at a sufficiently practical level. I was able to.
- Comparative Example A3 had some problems with stability over time because the number of moles of polyoxyethylene groups in the blended polyoxyethylene-added phytosterol was less than 5.
- Example A4 the polyoxyethylene group of the compound (I) was 5 to 50 mol, and the appearance, usability and stability over time were good.
- Example A5 since the polyoxyethylene group of the compound (I) was 50 or more, stickiness was observed during use.
- Example A9 was slightly translucent because the ratio of compound (I) / ultraviolet absorber was 1 or less.
- Examples A6 to A8 had good appearance, usability, and stability because the ratio of compound (I) / ultraviolet absorber was 1 or more.
- Compound (I) used in Example A10 is an ultraviolet absorber having only one 6-membered ring in the chemical structure and can be solubilized. It did not come.
- compound (I) used in Examples A11 to A13 is an ultraviolet absorber having two or more 6-membered rings in its chemical structure, its appearance and stability were good.
- each test was conducted using a formulation (external preparation) using general components.
- Each general component is water-soluble.
- Prepare each test product by mixing with ion-exchanged water to prepare aqueous phase parts and mixing with UV absorber and compound (I) dissolving parts in advance. It was.
- Example concerning water-containing composition [Test Example B] Based on a conventional method, compound (I) or other surfactant and a poorly water-soluble UV absorber are mixed and dissolved, and the parts are dissolved in a water-soluble dye (red 233) or a component to be stabilized. By mixing sodium salicylate, potassium 4-methoxysalicylate, tranexamic acid, sodium ascorbate in the aqueous phase, the test products (Examples or Comparative Examples) shown in Tables B1 to B6 were obtained, and the following determinations were made. Tests according to criteria were performed.
- B-1 Test Immediately after Preparation of Test Product
- (a) confirmation of dissolved state confirmation of dissolved state
- (b) confirmation of transparency (L value) confirmation of transparency (L value)
- (c) usability test were performed.
- the test methods and evaluation criteria for these B-1 lines were as follows: (a) Confirmation of dissolved state, (b) Confirmation of transparency (L value), (c) Usability test , And the same contents.
- Comparative Examples B1 and B2 use a surfactant that does not have a phytosteryl skeleton, so that the solubilizing ability is low and the poorly water-soluble UV absorber (bisethylhexyloxyphenolmethoxyphenyltriazine) is solubilized. It became clear that it was not suitable for. On the other hand, Examples B1 to B3 used Compound (I) and were able to solubilize the poorly water-soluble UV absorber at a sufficiently practical level.
- the poorly water-soluble UV absorber bisethylhexyloxyphenolmethoxyphenyltriazine
- Comparative Example B3 was slightly inferior in stability over time because polyoxyethylene-added phytosterol having a number of added polyoxyethylene groups of less than 5 was blended instead of compound (I).
- Example B4 compounded with compound (I) having an added polyoxyethylene chain of 5 to 50 mol, and had good appearance, usability, and stability over time.
- Example B8 was slightly translucent because the ratio of Compound (I) / poorly water-soluble UV absorber was 1 or less.
- Examples B5 to B7 had good appearance, usability, and stability because the ratio of compound (I) / poorly water-soluble UV absorber was 1 or more.
- the poorly water-soluble UV absorber used in Example B9 is a UV absorber having only one six-membered ring in the chemical structure and can be solubilized, but the best stability over time is obtained. It did not reach.
- the poorly water-soluble UV absorber used in Examples B10 to B12 is an UV absorber having two or more 6-membered rings in the chemical structure, the appearance and stability were good.
- ⁇ Test system B5> In the test system shown in Table B5, in addition to the essential components of the water-containing composition of the present invention, each test was conducted using a formulation (external preparation) using general components. Each general component is water-soluble, prepared in advance by mixing with ion-exchanged water to prepare an aqueous phase part, and mixing with a water-insoluble UV absorber and compound (I) dissolving part, Prepared.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(1)下記式(I)にて表されるポリオキシエチレン付加化合物(以下、化合物(I)ともいう)
HO(CH2CH2O)n-R (I)
[式中、Rはフィトステロール残基又はフィトスタノール残基を示し、nは5~100の数を示す。]
(2)水難溶性の紫外線吸収剤
(3)水
[A-1]ポリオキシエチレン付加化合物(化合物(I))の配合
本発明の含水組成物においては、上述のように、水と水難溶性の紫外線吸収剤と共に、化合物(I)が配合される。化合物(I)は、後述するように、上記式(I)の範囲内の1種のみの化合物として本発明の含水組成物に配合すること、及び、異なる2種以上の化合物の混合物として配合すること、が可能である。
本発明の含水組成物でおいては、水難溶性の紫外線吸収剤を1種又は2種以上配合して、これを可溶化又は水分散化することが必要である。水難溶性の紫外線吸収剤における水以外の溶媒に対する溶解性については特に限定されるものではない。なお、この水難溶性の紫外線吸収剤の配合は、水溶性の紫外線吸収剤の選択的な配合を妨げない。
本発明の含水組成物における水は、通常は、イオン交換水、精製水、又は、水道水である。組成物全体における、化合物(I)、及び、水難溶性の紫外線吸収剤の総量に対する残量、あるいは、組成物全体における、化合物(I)、水難溶性の紫外線吸収剤、及び、一般的な配合成分に対する残量を含有させることができる。
本発明の含水組成物においては、化合物(I)の存在により、本来は水に難溶性の紫外線吸収剤が容易に可溶化又は水分散化される。好ましくは、例えば、水難溶性の紫外線吸収剤を、化合物(I)に溶解又は分散させたパーツを調製し、これを、水相に混合して、可溶化又は分散させることにより、本発明の含水組成物を製造することができる。
[B-1]本発明の含水組成物との共通配合成分
本発明の安定化組成物は、上述した本発明の含水組成物において、水溶性の薬剤及び水溶性の色素の双方又はいずれか一方が、1種又は2種以上配合された含水組成物である。よって、本発明の安定化組成物の必須成分として配合される、(1)化合物(I)、(2)水難溶性の紫外線吸収剤、及び、(3)水、の配合については、上述した本発明の安定化組成物の(A-1)、(A-2)、及び、(A-3)、の記載に従う。
(1)水溶性色素
本発明の安定化組成物の安定化対象の水溶性色素は、特に限定されるものではないが、例えば、赤色3号(エリスロシン)、赤色102号(ニューコクシン)、赤色106号(アシッドレッド)、赤色201号(リソールルビンB)、赤色227号(ファストアシッドマゲンタ)、赤色230号の(1)(エリスロシンYS)、赤色203号の(2)(エリスロシンYSK)、赤色231号(フロキシンBK)、赤色232号(ローズベンガルK)、赤色401号(ビオラミンR)、赤色502号(ボンソー3R)、赤色503号(ボンソーR)、赤色504号(ボンソーSX)、赤色506号(ファストレッドS)、黄色202号の(2)(ウラニンK)、黄色4号(タートラジン)、黄色402号(ポーラエロー5G)、黄色403号の(1)(ナフトールエローS)、黄色406号(メタニールエロー)、緑色3号(ファーストグリーンFCF)、緑色201号(アリザリンシアニングリーンF)、緑色204号(ピラニンコンク)、緑色205号(ライトグリーンSF黄)、緑色401号(ナフトールグリーンB)、緑色402号(ギネアグリーンB)、青色1号(ブリリアントブルーFCF)、青色2号(インジゴカルミン)、青色202号(パテントブルーNA)、青色205号(アルファズリンFG)、褐色201号(レゾルシンブラウン)、紫色401号(アリズロールパープル)、黒色401号(ナフトールブルーブラック)等が挙げられる。
本発明の安定化組成物の安定化対象の水溶性薬剤は、特に限定されるものではないが、例えば、アスコルビン酸系美白剤として、L―アスコルビン酸(ビタミンC)が挙げられる。また、ビタミンC誘導体として、例えば、L-アスコルビン酸モノリン酸エステル、L-アスコルビン酸-2-硫酸エステル、dl-α-トコフェロール2-L-アスコルビン酸リン酸ジエステル等のアスコルビン酸無機塩エステル類;2-O-α-D-グルコピラノシル-L-アスコルビン酸等のアスコルビン酸-2-グリコシド等が挙げられる。
本発明の安定化組成物においては、化合物(I)の存在により、本来は水に難溶性の紫外線吸収剤が容易に可溶化又は水分散化される。好ましくは、例えば、水難溶性の紫外線吸収剤を、化合物(I)に溶解又は分散させたパーツを調製し、これを安定化対象である水溶性薬剤又は水溶性色素を含む水相に混合して、可溶化又は分散させることにより、本発明の安定化組成物を製造することができる。
上述のように、本発明の安定化方法は、実質的には、本発明の安定化組成物における、水溶性色素及び/又は水溶性薬剤の安定化方法であり、本発明の安定化組成物に関する実施を行うことは、必然的に本発明の安定化方法の実施と一致する。
[試験例A]
常法に基づき、化合物(I)若しくは他の界面活性剤と、紫外線吸収剤を混合して溶解し、当該パーツを水中にて混合することにより、表A1~表A6に示す試験品(実施例又は比較例)を得て、下記の判定基準による試験を行った。結果については、各表毎に個別に記載する。なお、本A群の例と、後述するB群の例を通じて、各表の配合量を示す欄における「-」は、0質量%であることを示す。さらに、「POE」とは「ポリオキシエチレン」の略称であり、「POP」とは「ポリオキシプロピレン」の略称である。
(a)溶解状態の確認
各試験品について、目視による溶解状態の確認試験を行った。判定基準は以下の通りである。
○: ほぼ透明状態である。
△: 白濁~半透明である。
×: 分離物が認められる。
各試験品について、透明度についてL値の計測による確認を行った。L値は、島津製作所社製の分光光度計(UV-160)を用い、コントロールとして蒸留水の透明度を100としたときの透明度として測定した。判定基準は、以下の通りである。
70~90未満: ほぼ透明である。
70未満: 白濁~半透明である。
測定不能: 分離物が認められる。
調製直後の各試験品について、専門パネル10名による使用感触テストを行った。判定基準は、以下の通りである。
△: 10人中3~4人が、べたつきがないと評価した場合
×: 10人中0~2人が、べたつきがないと評価した場合
(a)溶解状態の変化の確認
上記のごとく調製した試験品を50℃で1ヶ月保存し(以下、「50℃1M」とも表す)、再び、上記の要領でL値の測定を行った。そして、上記の試験品調製直後に計測したL値と、今回計測したL値の差により、経時的な安定性の評価を行った。判定基準は、以下の通りである。なお、今回計測したL値も併せて各表に記載する。
○: L値 ±5以内
△: L値 ±10以内
×: L値変化 ±10以上、又は、分離物が認められる
表A3に示す試験系では、化合物(I)と水難溶性物質の比率(質量比)が問題となるため、当該比率も表に示した。
表A5に示す試験系では、本発明の含水組成物の必須成分の他に、一般成分を用いた処方(外用剤)を採用して各試験を行った。各一般成分は水溶性であり、予め、イオン交換水に混合して水相パーツを調製して、紫外線吸収剤と化合物(I)の溶解パーツと混合することにより、各試験品の調製を行った。
[試験例B]
常法に基づき、化合物(I)若しくは他の界面活性剤と、水難溶性の紫外線吸収剤を混合して溶解を試み、当該パーツを、安定化対象成分である水溶性色素(赤色233号)又サリチル酸ナトリウム、4-メトキシサリチル酸カリウム、トラネキサム酸、アスコルビン酸ナトリウム、を水相中にて混合することにより、表B1~表B6に示す試験品(実施例又は比較例)を得て、下記の判定基準による試験を行った。
この系統の試験としては、(a)溶解状態の確認、(b)透明度(L値)の確認、(c)使用性試験、を行った。これらのB-1系統の試験の方法と評価基準は、上述したA-1系統において行った、(a)溶解状態の確認、(b)透明度(L値)の確認、(c)使用性試験、と同一の内容にて行った。
(a)溶解状態の変化の確認
この試験の方法と評価基準は、上述したA-2系統において行った、(a)溶解状態の変化の確認、と同一の内容にて行った。
各試験品について、色差についてΔEの計測による確認を行った。ΔE値は、島津製作所社製の分光光度計(UV-160)を用い、コントロールとして調製直後のサンプルを基準とした場合のΔE値として測定した。判定基準は、以下の通りである。
ΔE値 2以内 : 色の変化がほとんど認められない。
ΔE値 5以内 : 色の変化が多少認められる。
ΔE値 5以上 : 色の変化がかなり認められる。
表B3に示す試験系では、化合物(I)と水難溶性物質の比率(質量比)が問題となるため、当該比率も表に示した。
表B5に示す試験系では、本発明の含水組成物の必須成分の他に、一般成分を用いた処方(外用剤)を採用して各試験を行った。各一般成分は水溶性であり、予め、イオン交換水に混合して水相パーツを調製して、水難溶性の紫外線吸収剤と化合物(I)の溶解パーツと混合することにより、各試験品の調製を行った。
Claims (13)
- 下記成分(1)~(3)を含有する、含水組成物。
(1)下記式(I)にて表されるポリオキシエチレン付加化合物
HO(CH2CH2O)n-R (I)
[式中、Rはフィトステロール残基又はフィトスタノール残基を示し、nは5~100の数を示す。]
(2)水難溶性の紫外線吸収剤
(3)水 - ポリオキシエチレン付加化合物(I)に対する、水難溶性の紫外線吸収剤の配合量比が、質量比で1以上である、請求項1に記載の含水組成物。
- ポリオキシエチレン付加化合物(I)におけるフィトステロール残基又はフィトスタノール残基Rが、シトステロール残基、カンペステロール残基、スチグマステロール残基、ブラッシカステロール(brassicasterol)残基、アベナステロール(avenasterol)残基、エルゴステロール残基、シトスタノール残基、カンペスタノール残基、スチグマスタノール残基、ブラッシカスタノール(brassicastanol)残基、アベナスタノール(avenastanol)残基、及び、エルゴスタノール残基、からなる群から選ばれる1種又は2種以上である、請求項1又は2に記載の含水組成物。
- ポリオキシエチレン付加化合物(I)におけるnが5~50の数である、請求項1~3のいずれかに記載の含水組成物。
- 水難溶性の紫外線吸収剤が、6員環を2つ以上有する化学構造の紫外線吸収剤である、請求項1~4のいずれかに記載の含水組成物。
- 水難溶性の紫外線吸収剤が、UVA領域に吸収を持つ紫外線吸収剤である、請求項1~5のいずれかに記載の含水組成物。
- 水難溶性の紫外線吸収剤が、トリアジン誘導体である、請求項1~6のいずれかに記載の含水組成物。
- 含水組成物が外用組成物である、請求項1~7のいずれかに記載の含水組成物。
- 外用組成物の形態が化粧料又は皮膚外用剤である、請求項8に記載の含水組成物。
- 含水組成物が、外用組成物を製造するための基剤として用いられる組成物である、請求項1~9のいずれかに記載の含水組成物。
- 含水組成物が、水溶性の薬剤及び/又は水溶性の色素を含有する、請求項1~10のいずれかに記載の含水組成物。
- 水溶性の薬剤が、ビタミンC、ビタミンC誘導体、サリチル酸、サリチル酸誘導体、トラネキサム酸及びトラネキサム酸誘導体、からなる群から選ばれる1種又は2種以上である、請求項11に記載の含水組成物。
- 水溶性の薬剤及び/又は水溶性の色素を、下記成分(1)~(3)と含水組成物中において共存させて、当該薬剤及び/又は色素の安定性を向上させる、水溶性成分の安定化方法であって、下記ポリオキシエチレン付加化合物(I)に対する、水難溶性の紫外線吸収剤の配合量比は、質量比で1以上である、水溶性成分の安定化方法。
(1)下記式(I)にて表されるポリオキシエチレン付加化合物
HO(CH2CH2O)n-R (I)
[式中、Rはフィトステロール残基又はフィトスタノール残基を示し、nは5~100の数を示す。]
(2)水難溶性の紫外線吸収剤
(3)水
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/002,005 US20110129429A1 (en) | 2008-07-02 | 2009-07-01 | Water-Containing Composition |
CN2009801188123A CN102036686A (zh) | 2008-07-02 | 2009-07-01 | 含水组合物 |
EP09773504A EP2308512A4 (en) | 2008-07-02 | 2009-07-01 | WATER-CONTAINING COMPOSITION |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-172924 | 2008-07-02 | ||
JP2008-172922 | 2008-07-02 | ||
JP2008172924A JP4657324B2 (ja) | 2008-07-02 | 2008-07-02 | 含水組成物 |
JP2008172922A JP4657323B2 (ja) | 2008-07-02 | 2008-07-02 | 含水組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010001926A1 true WO2010001926A1 (ja) | 2010-01-07 |
Family
ID=41466018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/062036 WO2010001926A1 (ja) | 2008-07-02 | 2009-07-01 | 含水組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110129429A1 (ja) |
EP (1) | EP2308512A4 (ja) |
KR (1) | KR20110026441A (ja) |
CN (1) | CN102036686A (ja) |
TW (1) | TW201006506A (ja) |
WO (1) | WO2010001926A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013021775A1 (ja) * | 2011-08-05 | 2013-02-14 | 株式会社 資生堂 | 液状皮膚外用剤組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106659665A (zh) * | 2014-07-16 | 2017-05-10 | 莱雅公司 | 无油防晒组合物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0640886A (ja) | 1992-05-15 | 1994-02-15 | Shiseido Co Ltd | 皮膚外用剤 |
JPH06172153A (ja) | 1992-12-04 | 1994-06-21 | Kanebo Ltd | 美白化粧料 |
JP2002029915A (ja) * | 2000-07-10 | 2002-01-29 | Lion Corp | 皮膚化粧料 |
JP2003026560A (ja) * | 2001-07-12 | 2003-01-29 | Kanebo Ltd | 活性酸素消去剤、老化防止用皮膚化粧料、及び活性酸素消去能の安定化方法。 |
JP2005511586A (ja) | 2001-11-09 | 2005-04-28 | アストラゼネカ・アクチエボラーグ | エトキシル化フィトステロールおよびフィトスタノールの新規使用法 |
JP2006111620A (ja) * | 2004-09-16 | 2006-04-27 | Kose Corp | 水中油型液状組成物 |
JP2006327952A (ja) * | 2005-05-24 | 2006-12-07 | Shiseido Co Ltd | 水中油型乳化組成物及びその製造方法 |
WO2009084588A1 (ja) * | 2007-12-27 | 2009-07-09 | Shiseido Company, Ltd. | 外用組成物として用いることのできる含水組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1339029C (en) * | 1988-06-20 | 1997-04-01 | Hiroyuki Kakoki | Transparent composition |
DE19814739A1 (de) * | 1998-04-02 | 1999-10-07 | Basf Ag | Verwendung von Polyalkylenoxid-haltigen Pfropfpolymerisaten als Solubilisatoren |
US20080131381A1 (en) * | 2006-09-29 | 2008-06-05 | Chaudhuri Ratan K | Methods for photostabilizing ingredients within cosmetics, personal care and household products and compositions obtained therefrom |
US8580235B2 (en) * | 2008-06-20 | 2013-11-12 | Shiseido Company, Ltd. | Hair cosmetic |
-
2009
- 2009-07-01 WO PCT/JP2009/062036 patent/WO2010001926A1/ja active Application Filing
- 2009-07-01 CN CN2009801188123A patent/CN102036686A/zh active Pending
- 2009-07-01 KR KR1020107029575A patent/KR20110026441A/ko not_active Application Discontinuation
- 2009-07-01 EP EP09773504A patent/EP2308512A4/en not_active Withdrawn
- 2009-07-01 US US13/002,005 patent/US20110129429A1/en not_active Abandoned
- 2009-07-02 TW TW098122472A patent/TW201006506A/zh unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0640886A (ja) | 1992-05-15 | 1994-02-15 | Shiseido Co Ltd | 皮膚外用剤 |
JPH06172153A (ja) | 1992-12-04 | 1994-06-21 | Kanebo Ltd | 美白化粧料 |
JP2002029915A (ja) * | 2000-07-10 | 2002-01-29 | Lion Corp | 皮膚化粧料 |
JP2003026560A (ja) * | 2001-07-12 | 2003-01-29 | Kanebo Ltd | 活性酸素消去剤、老化防止用皮膚化粧料、及び活性酸素消去能の安定化方法。 |
JP2005511586A (ja) | 2001-11-09 | 2005-04-28 | アストラゼネカ・アクチエボラーグ | エトキシル化フィトステロールおよびフィトスタノールの新規使用法 |
JP2006111620A (ja) * | 2004-09-16 | 2006-04-27 | Kose Corp | 水中油型液状組成物 |
JP2006327952A (ja) * | 2005-05-24 | 2006-12-07 | Shiseido Co Ltd | 水中油型乳化組成物及びその製造方法 |
WO2009084588A1 (ja) * | 2007-12-27 | 2009-07-09 | Shiseido Company, Ltd. | 外用組成物として用いることのできる含水組成物 |
Non-Patent Citations (2)
Title |
---|
F. D. GUNSTONE; B. G. HERSLOF: "A Lipid Glossary", 1992, THE OILY PRESS, AIR |
See also references of EP2308512A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013021775A1 (ja) * | 2011-08-05 | 2013-02-14 | 株式会社 資生堂 | 液状皮膚外用剤組成物 |
JP2013053130A (ja) * | 2011-08-05 | 2013-03-21 | Shiseido Co Ltd | 液状皮膚外用剤組成物 |
US10493013B2 (en) | 2011-08-05 | 2019-12-03 | Shiseido Company, Ltd. | Liquid skin-conditioning composition |
Also Published As
Publication number | Publication date |
---|---|
KR20110026441A (ko) | 2011-03-15 |
TW201006506A (en) | 2010-02-16 |
US20110129429A1 (en) | 2011-06-02 |
EP2308512A1 (en) | 2011-04-13 |
CN102036686A (zh) | 2011-04-27 |
EP2308512A4 (en) | 2012-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102368163B1 (ko) | 피부 상의 백화 효과를 감소시키는 코팅된 티타늄 디옥사이드 | |
JP4657323B2 (ja) | 含水組成物 | |
WO2010026755A1 (ja) | 日焼け止め化粧料 | |
ES2940078T3 (es) | Nuevo sistema solubilizante de filtros solares orgánicos liposolubles | |
JP4657324B2 (ja) | 含水組成物 | |
WO2010001926A1 (ja) | 含水組成物 | |
JP2005206473A (ja) | 皮膚外用剤 | |
JP2018021085A (ja) | 外用組成物 | |
JP2017503021A (ja) | Uvフィルターの可溶化 | |
JP5545696B2 (ja) | 外用組成物として用いることのできる含水組成物 | |
JP2013047206A (ja) | 紫外線吸収剤を含有する微細エマルション組成物並びに化粧料 | |
JP2019085424A (ja) | 塗布時に澄明な高度uv保護のアルコール非含有エマルション系 | |
JP6262146B2 (ja) | サンケア製剤及び方法 | |
JP6178601B2 (ja) | p−クマル酸を含有した組成物 | |
US8153105B1 (en) | Sunblock composition with photostabilizer and method of preparation | |
JP2006298788A (ja) | 半透明化粧料の製造方法 | |
JP2022070288A (ja) | 外用組成物 | |
JP6178602B2 (ja) | p−クマル酸を含有した組成物 | |
CN115813792A (zh) | 广谱的防晒组合物 | |
JP2018062485A (ja) | 外用組成物、及びそれを用いた化粧料 | |
US20200129417A1 (en) | Stabilized cosmetic compositions | |
JP2007308389A (ja) | 日焼け止め化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980118812.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09773504 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20107029575 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009773504 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13002005 Country of ref document: US |